NCT06754501View on ClinicalTrials.gov

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2029

Conditions
Cancer
Interventions
DRUG

Atezolizumab

Given by vein

DRUG

Tiragolumab

Given by vein

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Strategic Alliance

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06754501 - A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary | Biotech Hunter | Biotech Hunter